Logo image of PAHC

PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Price, Forecast & Analysis

USA - NASDAQ:PAHC - US71742Q1067 - Common Stock

42.06 USD
+0.2 (+0.48%)
Last: 10/31/2025, 8:06:48 PM
42.06 USD
0 (0%)
After Hours: 10/31/2025, 8:06:48 PM

PAHC Key Statistics, Chart & Performance

Key Statistics
Market Cap1.70B
Revenue(TTM)1.30B
Net Income(TTM)48.26M
Shares40.53M
Float20.20M
52 Week High43.65
52 Week Low16.16
Yearly Dividend0.48
Dividend Yield1.15%
EPS(TTM)2.09
PE20.12
Fwd PE15.66
Earnings (Next)11-05 2025-11-05/amc
IPO2014-04-11
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PAHC short term performance overview.The bars show the price performance of PAHC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

PAHC long term performance overview.The bars show the price performance of PAHC in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200 250

The current stock price of PAHC is 42.06 USD. In the past month the price increased by 9.76%. In the past year, price increased by 81.45%.

PHIBRO ANIMAL HEALTH CORP-A / PAHC Daily stock chart

PAHC Latest News, Press Relases and Analysis

PAHC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 39.24 816.66B
JNJ JOHNSON & JOHNSON 18.2 454.86B
AZN ASTRAZENECA PLC-SPONS ADR 18.56 255.48B
NVS NOVARTIS AG-SPONSORED ADR 13.83 239.64B
NVO NOVO-NORDISK A/S-SPONS ADR 12.81 219.77B
MRK MERCK & CO. INC. 9.87 214.76B
PFE PFIZER INC 7.27 140.15B
SNY SANOFI-ADR 11.52 123.27B
GSK GSK PLC-SPON ADR 7.73 94.25B
BMY BRISTOL-MYERS SQUIBB CO 7.02 93.77B
ZTS ZOETIS INC 23.17 63.86B
TAK TAKEDA PHARMACEUTIC-SP ADR 48 42.45B

About PAHC

Company Profile

PAHC logo image Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.

Company Info

PHIBRO ANIMAL HEALTH CORP-A

Glenpointe Centre East, 3Rd Floor, 300 Frank W. Burr Blvd., Suite 21

Teaneck NEW JERSEY 07666 US

CEO: Jack C. Bendheim

Employees: 1940

PAHC Company Website

PAHC Investor Relations

Phone: 12013297300

PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ

Can you describe the business of PHIBRO ANIMAL HEALTH CORP-A?

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 2,475 full-time employees. The company went IPO on 2014-04-11. The company develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. The company has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.


Can you provide the latest stock price for PHIBRO ANIMAL HEALTH CORP-A?

The current stock price of PAHC is 42.06 USD. The price increased by 0.48% in the last trading session.


Does PAHC stock pay dividends?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a dividend yield of 1.15%. The yearly dividend amount is currently 0.48.


What is the ChartMill technical and fundamental rating of PAHC stock?

PAHC has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How is the valuation of PHIBRO ANIMAL HEALTH CORP-A (PAHC) based on its PE ratio?

The PE ratio for PHIBRO ANIMAL HEALTH CORP-A (PAHC) is 20.12. This is based on the reported non-GAAP earnings per share of 2.09 and the current share price of 42.06 USD.


Can you provide the growth outlook for PHIBRO ANIMAL HEALTH CORP-A?

The Revenue of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is expected to grow by 14.11% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the next earnings date for PAHC stock?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) will report earnings on 2025-11-05, after the market close.


PAHC Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to PAHC. When comparing the yearly performance of all stocks, PAHC is one of the better performing stocks in the market, outperforming 93.99% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PAHC Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PAHC. While PAHC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PAHC Financial Highlights

Over the last trailing twelve months PAHC reported a non-GAAP Earnings per Share(EPS) of 2.09. The EPS increased by 75.63% compared to the year before.


Industry RankSector Rank
PM (TTM) 3.72%
ROA 3.55%
ROE 16.89%
Debt/Equity 2.46
Chartmill High Growth Momentum
EPS Q2Q%39.02%
Sales Q2Q%38.62%
EPS 1Y (TTM)75.63%
Revenue 1Y (TTM)27.38%

PAHC Forecast & Estimates

9 analysts have analysed PAHC and the average price target is 33.32 USD. This implies a price decrease of -20.78% is expected in the next year compared to the current price of 42.06.

For the next year, analysts expect an EPS growth of 28.48% and a revenue growth 14.11% for PAHC


Analysts
Analysts48.89
Price Target33.32 (-20.78%)
EPS Next Y28.48%
Revenue Next Year14.11%

PAHC Ownership

Ownership
Inst Owners105.31%
Ins Owners0.65%
Short Float %4.78%
Short Ratio3.03